Bedtime Fibromyalgia Therapy TNX-102 SL Sees Faster-than-expected Trial Enrollment

Bedtime Fibromyalgia Therapy TNX-102 SL Sees Faster-than-expected Trial Enrollment
Enrollment in the RELIEF Phase 3 trial assessing TNX-102 SL (sublingual cyclobenzaprine) as a nighttime treatment for pain and disturbed sleep due to fibromyalgia has been faster than expected, according to Tonix Pharmaceuticals, therapy's developer. The company now anticipates enrollment completion from July to September, and top-line results later this year instead of next year. The trial (NCT04172831) is seeking to recruit 470 adults with fibromyalgia, ages 18-65, across several U.S. sites. More information on contacts and locations is available here. “We are pleased to announce that we will achieve our recruitment goal ahead of schedule,” Seth Lederman, MD, CEO of Tonix, said in a press release. “We have worked diligently to ensure the safe and timely recruitment of the RELIEF trial before and during the
Subscribe or to access all post and page content.